

# NIH Public Access

**Author Manuscript** 

Biol Psychiatry. Author manuscript; available in PMC 2016 March 01.

Published in final edited form as:

Biol Psychiatry. 2015 March 1; 77(5): 434–444. doi:10.1016/j.biopsych.2014.08.020.

## Anticipatory Reward Processing in Addicted Populations: A Focus on the Monetary Incentive Delay Task

Iris M. Balodis<sup>1,\*</sup> and Marc N. Potenza<sup>1,2,3</sup>

<sup>1</sup>Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA <sup>2</sup>Department of Neurobiology, Yale University School of Medicine, New Haven, CT, USA <sup>3</sup>Child Study Center, Yale University School of Medicine, New Haven, CT, USA

### Abstract

Advances in brain imaging techniques have allowed neurobiological research to temporally analyze signals coding for the anticipation of rewards. In addicted populations, both hypo- and hyperresponsiveness of brain regions (e.g., ventral striatum) implicated in drug effects and reward system processing have been reported during anticipation of generalized reward. Here, we discuss the current state of knowledge of reward processing in addictive disorders from a widely used and validated task: the Monetary Incentive Delay Task (MIDT). The current paper constrains review to those studies applying the MIDT in addicted and at-risk adult populations, with a focus on anticipatory processing and striatal regions activated during task performance, as well as the relationship of these regions with individual difference (e.g., impulsivity) and treatment outcome variables. We further review drug influences in challenge studies as a means to examine acute influences on reward processing in abstinent, recreationally using and addicted populations. Here, we discuss that generalized reward processing in addicted and at-risk populations is often characterized by divergent anticipatory signaling in the ventral striatum. Although methodological/task variations may underlie some discrepant findings, anticipatory signaling in the ventral striatum may also be influenced by smoking status, drug metabolites and treatment status in addicted populations. Divergent results across abstinent, recreationally using and addicted populations demonstrate complexities in interpreting findings. Future studies will benefit from focusing on characterizing how impulsivity and other addiction-related features relate to anticipatory striatal signaling over time. Additionally,

<sup>© 2014</sup> Society of Biological Psychiatry. All rights reserved.

<sup>&</sup>lt;sup>\*</sup>Corresponding Author: Iris M. Balodis, PhD, Yale University School of Medicine, 1 Church Street, Rm 731, New Haven, CT 06519, Tel: 203-737-2668, iris.balodis@yale.edu.

**Disclosures/Conflicts of Interest:** The authors report that they have no biomedical financial interests or potential conflicts of interest with respect to the content of this manuscript. Dr Potenza has received financial support or compensation for the following: Dr. Potenza has consulted for Ironwood and Lundbeck; has received research support from Mohegan Sun Casino, the National Center for Responsible Gaming, and Psyadon pharmaceuticals; has participated in surveys, mailings or telephone consultations related to drug addiction, impulse control disorders or other health topics; has consulted for law offices and the federal public defender's office in issues related to impulse control disorders; provides clinical care in the Connecticut Department of Mental Health and Addiction Services Problem Gambling Services Program; has performed grant reviews for the National Institutes of Health and other agencies; has guest-edited journal sections; has given academic lectures in grand rounds, CME events and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

identifying how anticipatory signals recover/adjust following protracted abstinence will be important in understanding recovery processes.

### Keywords

Addiction; impulsivity; monetary incentive delay task; reward; striatum; anticipation

### Introduction

Reward processing contributes importantly to adaptive decision-making by facilitating the prediction of future events. In particular, neural processes during anticipation occur immediately prior to choice and are thereby optimally ordered in time to influence decisionmaking(1). Alterations in anticipation-related neural signals could be disadvantageous and compromise abilities to select between different courses of action. Understanding reward processes has significant implications for many psychiatric conditions, particularly addictive disorders, where drug-seeking behavior is attributed to altered reward/reinforcement sensitivities. Thus, neurobiological research has focused not only on understanding sensitivities to drug cues, but also to non-drug rewards, and how alterations in generalized reward processing may represent a vulnerability and/or a maintenance factor in addicted populations. Theories, including Reward Deficiency Syndrome(2), Allostatic Hypothesis(3), Incentive Salience(4), and Temporal-Difference Reinforcement Learning(5), emphasize hypoor hyper-responsiveness, particularly in the ventral striatum (VS), across reward processing phases and addiction stages. However, neuroimaging research of reward processing has produced seemingly ambiguous and contradictory findings. While differences in findings may relate to methodological/sample characteristics, they also demonstrate emerging theoretical and empirical sophistication in understanding cognitive components of addiction neurobiology. These refinements include consideration of additional constituents underlying cognitive processes in addiction: saliency, valence, magnitude, choice, guessing and motor preparation, all of which may influence reward signals. Conjointly, technological advances provide greater anatomical specificity in neuroimaging; for example, in anatomically dissecting the striatum and identifying complex, dissociable functional roles for its subdivisions(6-9). These efforts together with more rigorous approaches being used in neuroimaging studies (e.g., multiple-comparison corrections, jittered stimuli presentations), contribute to a matured understanding of generalized reward processing.

This review seeks to synthesize reward processing findings in addictions, identify research gaps and future study directions. Anticipatory-reward-processing studies employing a widely used, well-validated task, the Monetary Incentive Delay Task (MIDT), are reviewed in addicted and at-risk adults, with a focus on striatal areas implicated during anticipatory phases. Even limiting discussion to the MIDT, various task versions exist, together with different methodological and modeling approaches applied (Table 1). Although methodological/task variations may underlie some discrepant findings, MIDT studies of generalized reward processing in addicted and at-risk populations have produced divergent findings. We further explore how anticipatory VS signaling may be influenced by smoking status, the presence of drug metabolites and treatment status in addicted populations.

### 1. MIDT: Advantages, assumptions and unanticipated findings

**1.1. Brief history**—The MIDT is integrated within theories of human decision-making and on how reward expectations shape behavior. The task, developed for scanning studies by Knutson, Hommer and colleagues, is modeled on an instrumental conditioning task developed by Schultz for use in animal neurophysiological studies (1,10-13). The task effectively explores the premises of multiple theories underlying addictions by parsing aspects of valence, magnitude, as well as motivational from hedonic stages of reward processing, and permitting study of whether distinctions in these domains recruit divergent neuroanatomical and neurochemical substrates. This decomposition of elements empirically integrates computational theories to clarify mechanisms of reinforcement learning. In animal models, probabilistic reward delivery guides associative learning by shifting phasic dopaminergic signaling to cues predicting reward(10,14). Similarly, probabilistic reward delivery on the MIDT increases anticipatory activity in the human VS(11,12), a key projection area of midbrain dopaminergic neurons. Thus, anticipatory processing provides a neural account of subjective cue value; a composite of an individual's current reward potential estimate together with the accrued learning across previous trials. Accordingly, this incentive cue salience can gauge incongruencies between experienced reward and anticipated rewards, enabling a framework to test reward-based learning theories(15-17) and how neural responses may change with experienced or predicted reward.

This framework also applies to learning components in addiction, where heightened anticipatory responding to drug cues may trigger motivational and emotional states related to craving; in contrast, other types of reinforcers may be devalued, thereby maintaining the addiction cycle(3,18). Thus, decoding the distinct neurocircuitry generating this anticipatory affect has implications for understanding approach and avoidance behavior on a second-to-second timescale, with the possibility of an improved index of affect dynamics and resultant behavior in both healthy and addicted populations(1,19).

The MIDT has a low cognitive demand and simple learning component; participants are instructed to respond to a target as quickly as possible, without learning complicated contingencies or making decisions. As such, it bypasses many cognitive variables such as guessing and choice inherent in decision-making tasks (e.g., the Iowa Gambling Task), which may influence reward processing. The MIDT permits examining generalized reward processing using monetary incentives, which are generally valued, scalable, and can be positive and negative in value(20). Moreover, this task has the advantage of assessing individual sensitivity to non-drug related reward processing, potentially compromised in addicted populations. Specifically, the task separates reward phases, through modeling reward anticipation and receipt. While heightened sensitivity to drug-related cues is observed in addicted populations(21), the MIDT allows interrogation of how generalized anticipatory reward processing may be altered in addiction. Nevertheless, even though similar behavioral performance and subjective ratings suggest comparable motivation among healthy and addicted populations, differences specific to monetary valuations on neural measures may still exist(22).

The original task is described in detail elsewhere(1,11,12,23). Briefly, during the first, anticipatory phase of the task, an individual observes a cue signaling the trial type (i.e. win,

loss or neutral), whereafter a target appears on the screen for a variable duration requiring that the subject respond with a button press. In the subsequent outcome phase of the task, an individual receives performance feedback and is updated on cumulative earnings. Importantly, this design disentangles the motivational from hedonic aspects of reward(12) and on a neurobiological level demonstrates spatial distinction in striatal versus medial prefrontal cortex (mPFC) recruitment during anticipatory and outcome processing, respectively(12,13). Therefore, VS and mPFC activation during specific MIDT phases may provide measures of neural sensitivities to reward anticipation and receipt to non-drug rewards.

The VS, encompassing the nucleus accumbens (NAc), is considered a fundamental region linking motivation and action(24) and where addictive drugs exert their rewarding effects (25,26). The finding that anticipatory reward processing during the MIDT activates the VS parallels findings in animal literature(27), providing a unifying account of how brain signals code incentive stimuli. However, a meta-analysis of MIDT studies(1) identified activation foci during gain versus non-gain contrasts in brain areas whose anatomical coordinates more closely correspond with the caudate or dorsal striatum (DS) rather than the NAc. This meta-analysis finding was somewhat unanticipated given that the VS and DS have been ascribed functionally dissociable roles in the reward system(6,28,29). The use of these meta-analysis coordinates as regions of interest (ROIs) in subsequent MIDT studies has led to application of 'NAc' and 'VS' to areas corresponding more closely with DS regions. Accurate identification of striatal regions is key in clarifying and understanding many study findings, particularly as a locus-ofcontrol shift from VS to DS is posited to underlie the transition from voluntary to habitual drug use(30). Potential mislabeling of striatal areas may contribute to ambiguous findings and possibly obscure functional distinctions; therefore, the current review describes striatal areas based on their anatomical coordinates.

**1.2.** Dopaminergic signaling and the MIDT—Analogous to electrophysiological studies demonstrating dopamine (DA) neurons encoding differences between the anticipated reward relative to the experienced one, an important assumption underlying MIDT performance is that VS activity reflects endogenous DA signaling (10,31). To date, only 2 human studies have directly examined the relationship between functional and neurochemical activity using Positron Emission Tomography (PET) and fMRI activation during the MIDT in the same participants. While the first study(32), reporting uncorrected results, found a relationship between reward-related [<sup>11</sup>C]raclopride displacement during PET and VS activity during MIDT performance, a subsequent study did not(33). This latter study, however, reported  $[^{11}C]$ raclopride binding potential changes in the posterior caudate, potentially affected by motor components involved with the button press. Nonetheless, the absence of observable <sup>[11</sup>C]raclopride displacement on a task with intermingled rewarding and non-rewarding conditions may prove difficult for the temporal resolution of PET imaging. More broadly, striatal DA release may not fully encompass functional changes captured during fMRI-indeed, similar functional-neurochemical investigations in other monetary reward/novelty tasks have reported *decreases*, rather than expected increases in DA transmission during unpredictable rewards(34,35). In the case of addicted populations, understanding alterations in DA release may further be complicated by striatal adaptations in dopaminergic receptor affinity, reuptake or availability(36); a better understanding of neurovascular coupling between dopaminergic

alterations and relative cerebral blood volume is necessary for interpreting how the BOLD signal relates to endogenously released DA. An imbalance in tonic-phasic signaling could differentially impair DA system regulation at different addiction stages; while phasic dopaminergic cell firing may convey anticipatory signaling(37,38), tonic signaling modulates these phasic bursts(39). Chronic drug exposure increases tonic activity, resulting in attenuated phasic signaling(39). Altogether, these findings reveal that the relationship between striatal BOLD changes during the MIDT and DA activity remains to be clarified; functional– neurochemical links may be only partially dopamine-dependent, and may represent a more heterogeneous signal reflecting other neurotransmitter systems, or even indicate differences in the excitatory tone of cells as of yet not clearly understood.

**1.3. Is neutral 'normal'? Modeling assumptions and interpretations**—A pragmatic consideration relates to the MIDT contrasts applied to examine specific constructs. The design permits the investigation of contrasts among multiple dimensions, including between different reward phases (i.e. anticipation versus outcome), valence (i.e. wins versus losses) as well as parametric responses (e.g. \$5 vs \$1 wins). Most commonly, however, investigations consist of gain versus non-gain contrasts across each of the anticipatory or the outcome phase, in order to isolate specific constructs of interest (i.e. control for visual stimuli, button press etc.). Thus the non-gain (sometimes referred to as 'neutral' or 'no outcome') in which participants win or lose \$0 is used as a type of baseline to effectively limit the influence of non-valence related activity. Thus a non-gain contrast presents a more nuanced modeling of the brain data, relative to baseline conditions (e.g., looking at a fixation cross). Even so, this contrast presumes that non-gain-related activity is comparable as a baseline between the 2 experimental groups – an often-untested assumption. Alterations occurring during the non-gain condition (e.g. blunted/ heightened signaling) could significantly alter findings of a double-contrast, when examining between-group differences.

Another assumption underlying the MIDT is the absence of behavioral differences on the task: while this can be considered problematic(40), it represents an effective approach for examining neural effects of the task that are not confounded by group differences in performance. Together with faster reaction times to rewarding versus neutral trials, similar success rates are important in establishing comparable motivation across participants. Task calibration during the practice session is meant to preclude behavioral differences and minimize learning effects; however, neural activity during scanning may still partly reflect learning differences in task acquisition, rather than reward processing *per se*. According to reward prediction theory, an individual still learning the task in the scanner may produce less anticipatory activity and greater outcome processing as the neural signals predicting reward delivery have not yet developed. Additionally, the anticipation phase includes not only the anticipation of the potential reward, but also the motivation to work for the reward, thereby further complicating interpretations (41).

### 2. MIDT findings in addicted populations

The first MIDT studies examining reward processing in addiction were conducted in alcoholdependent (AD) populations. Two early studies(42,43) report diminished anticipatory VS processing in detoxified, inpatient AD males relative to healthy controls (HC), during both

gain and loss conditions (Table 1). Many significant between-group differences emerge during anticipatory and not outcome phases of reward processing(43), suggesting greater interindividual differences sensitivities to anticipatory responses(44). However, two other AD studies(45,46) found no anticipatory differences in inpatients undergoing AD treatment; notably, all patients were regular smokers, with a majority meeting current/past dependence for non-alcohol drugs, mostly cocaine (discussed below). In one study(46), a modified MIDT included 'frustration trials' where participants were required to repeat some trials to obtain rewards, thereby examining anticipatory processes involving greater persistence. These frustration trials revealed an increased VS hemodynamic response (across groups) to the first, but not the second response trial(46); specifically, the AD group exhibited greater VS deactivation during frustration trials. Although deactivation could denote greater sensitivity to non-predicted non-rewards(40), it may also indicate an accelerated decline in motivation, since VS activation also reflects the effort to work for a reward (41). Another MIDT study(45), controlling for motor-preparatory effects during anticipation, found that AD groups did not differ from controls in VS recruitment during pre-response reward anticipation; however, postresponse anticipatory VS activity in AD subjects did not survive multiple comparison correction, suggesting lowered VS activation in this group.

In nicotine dependence (ND), current smokers exhibit reduced valence-related anticipatory activity in the left VS, anterior cingulate cortex (ACC) and right superior frontal gyrus during MIDT performance(47). Increased developmental and longitudinal studies will clarify whether hypoactive VS anticipatory signaling represents a neurobiological precursor for substance use, with subsequent substance use additionally attenuating this signaling. Indeed, chronic nicotine administration may blunt reward signals in fronto-striatal areas and/or synergistically combine with other drugs or drug metabolites. For example, relative to non-users, chronic cannabis users who also smoke cigarettes exhibit reduced reward anticipation on the MIDT in VS, caudate, putamen and prefrontal cortical areas; however, when controlling for smoking status with a ND control group, chronic cannabis users do not differ in VS recruitment, while altered recruitment in caudate, putamen and prefrontal areas still emerge(48). These findings highlight the benefit of including a smoking control group when examining other addicted populations (that frequently exhibit ND comorbidity).

Nevertheless, another study with matched nicotine use across experimental groups found *increased* right VS anticipatory activation relative to controls using a modified MIDT(49). The conflicting findings across the two cannabis-related studies may be accounted for by analytic differences (the latter contrasted reward activity relative to a fixation cross, rather than a neutral condition). More likely, however, this seemingly divergent result may relate to a distinct difference between participants: inclusion criteria for one study required negative urine toxicologies(48), whereas a positive THC urine screen was requisite in the other(49). The presence of THC or related metabolites, therefore, underscores a potential role for residual intoxication or partial withdrawal when examining signals in chronic drug users with varying stages of abstinence. In occasional users, a positive urine screen may reveal residual intoxication with subacute drug effects, whereas for others it could reflect partial withdrawal, with potentially different influences on neural activities.

Similarly, the potential roles of drugs or drug metabolites and abstinence stages may account for seemingly ambiguous findings reported in cocaine dependence (CD). Increased anticipatory activity in the caudate and right insula was observed in CD in one study(50), while another(51) reported diminished anticipatory processing in the dorsal caudate in CD. The former study investigated a treatment-seeking group with very recent cocaine use (some individuals reporting cocaine use at or very close to the scan date), whereas the latter included patients with 1-2 years of abstinence. Another study(52) using an MIDT variant parsing the anticipation phase into prospect and anticipation phases(53) showed that current and former CD groups differed comparably from a non-addicted group. No significant striatal differences in anticipatory gain or loss processing were observed when contrasting former versus current CD groups(52). Notably, however, the majority of participants in the former CD group included participants with current ND, with roughly <sup>1</sup>/<sub>4</sub> of the sample methadone-maintained, thereby making it difficult to assess incentive processing unmasked by other drug effects (see section 3). In sum, findings across CD studies suggest that clinical differences including treatmentseeking status, length of abstinence, and drugs or drug metabolites (whether in residual intoxication or partial withdrawal) may be important contributors explaining some of the variability in findings in addiction studies.

The expanded addiction category in DSM-5 now includes the first non-substance-based addictive disorder, gambling disorder (GD)(54). MIDT studies in GD investigate the unique situation in which disorder-related cues are in fact monetary; they also interrogate reward-processing mechanisms in a non-substance addiction. One MIDT study of individuals with GD reported diminished frontostriatal activity during both anticipation and outcome of wins and losses, relative to HCs(55). Another study(56) reported diminished ventromedial caudate activation in GD, relative to both an obsessive-compulsive disorder (OCD) and HC group. Importantly, participants in this latter study had GD for less than 5 years, with no other comorbidities. Across both studies, striatal signaling appears less valenced, in that diminished activity is evident across wins and loss relative to comparison groups, a finding reminiscent of those reported in substance-dependent populations(42,43).

### 2. Anticipatory striatal associations with addiction characteristics

The relationships between anticipatory striatal activity and impulsivity-related constructs appear across addictive disorders and have significant implications for research and treatment efforts. An association between VS activity and impulsivity during anticipatory processing was initially observed in AD(43). This relationship between heightened impulsivity and reduced anticipatory VS signaling has also been noted in adult Children of Alcoholics (COAs) (53) and in GD(55). VS anticipatory activity also relates to substance use; in AD, it correlates inversely with alcohol craving (42). In ND, plasma nicotine concentrations negatively correlate with signal change in the VS and putamen(47). These correlations demonstrate a rather consistent inverse relationship between addiction characteristics of drug intake with neural measures of reward processing. Notably, many of the relationships between addiction characteristics and VS activity occur exclusively in the addicted or at-risk population, suggestive of an important marker of motivational mechanisms underlying addiction vulnerability(57).

An important future direction involves the use of developmental models and monitoring throughout treatment and recovery. For example, in individuals with CD, months of treatment correlates positively with reward anticipation in the left caudate, but two studies demonstrate that abstinence duration in CD correlates negatively with the VS(51,52); as such, striatal reactivity to reward anticipation and outcome may dynamically change with treatment and abstinence progression. Accordingly, discrepant findings, particularly in CD populations, may reflect different addiction stages, with potentially different roles for the DS and VS relating to abstinence and length of treatment(51). These findings may reflect not only the direction but also lability of the VS signal: the VS may be more reactive during active addiction (and acute substance use) and during the onset of abstinence, but may become less reactive during prolonged abstinence(51). Diminished DS response during reward anticipation may also occur during abstinence, yet may over the long term provide a marker of treatment success. These possibilities warrant direct examination.

### 3. Drug challenges

Drug challenges in MIDT studies in addicted populations may help disentangle state versus trait effects and highlight complexities in interpreting findings and controlling for smoking status across populations. To date, no study has directly examined the effects of acute cocaine administration on the MIDT; however, two studies examining dopaminergic challenges with commonly abused stimulants demonstrate reductions in anticipatory VS signaling in nonaddicted populations. While dextroamphetamine administration may blunt anticipatory-related VS activation, it may also extend the duration of the signal, thereby altering endogenous tonic rather than phasic signaling(58). Similar to dextroamphetamine, an oral methylphenidate (MPH) challenge in healthy males produced reduced anticipatory signaling, but increases in recreational D-amphetamine (dAMPH) users(59). In contrast, during placebo administration, recreational dAMPH users show reduced VS responding relative to non-users, suggesting altered striatal function even with recreational dAMPH use. Given the exploratory and crosssectional nature of these studies, more longitudinal research is necessary to disentangle developmental from potential neurotoxic effects occurring from recreational drug use. Nonetheless, these different findings in placebo versus drug and non-users versus recreational users may account for findings in MIDT populations with positive or unverified toxicology screens. For example, subacute drug effects may stimulate incentive processing, alter the lability of VS signalling and modify VS-impulsivity relationships(49,50).

Nicotine patch administration in a smoking population highlights state- versus trait-related changes in motivational processes. Specifically, in a MIDT separating anticipatory valence from magnitude, attenuated VS activity during anticipatory valence showed a state-specific change in incentive processing in smokers during nicotine exposure(47). Together with increased DS activity during anticipatory magnitude-processing in smokers during the nicotine patch, these results suggest important modulatory effects of this drug in incentive processing in smokers. Future studies should examine anticipatory signaling in non-smokers as well as 'chipper' groups following a nicotine patch to further disentangle acute versus chronic effects of the drug on the brain (i.e., given a possibly sensitized response in ND). Notably, alterations in receptor availability between healthy, recreationally-using, and addicted populations may further complicate interpretations. For example, compromised D2 DA receptor occupancy in

In sum, the implication of these findings in smoking groups is wide-ranging, particularly given the high rates of ND in many psychiatric populations. Considering nicotine's effect on the reward system, these results emphasize the importance of carefully monitoring smoking chronicity and nicotine intake prior to scanning, as well as potentially including a smoker control group when examining other populations.

### **Conclusions and future directions**

The findings from MIDT studies of addicted populations suggest altered anticipatory processing in the VS relative to control populations. While many studies report attenuated VS activity in an addicted/at-risk population, such findings are not consistently ascertained. Discrepancies in MIDT findings may not only be due to task design, but also to acute drug effects, particularly nicotine, as well as addiction phase. Additionally, results suggest that individual differences in fronto-striatal recruitment, particularly the VS, reflect impulsivity and addiction-related characteristics. Taken together, there may exist both trait and state considerations in understanding the neural correlates of reward anticipation in addictions. Task design should streamline contrasts (e.g. limiting the influence of non-valence-related activity through contrasts that control for motor preparation, visual stimuli, etc.) and include loss trials to prevent/limit adaptation to rewards(60). Indeed, systematically evaluating how loss processing may differ in addicted populations remains difficult, as many studies do not report loss trial findings(50-53,60) or even include them(44,48,61,62). The latter trial structure may influence incentive processing as individuals habituate to receiving rewards. Studies reporting loss trial results often describe similar striatal responses to those evidenced during gain>neutral contrasts(42,43,46,49,55-57,63), although some studies report divergent findings(49,58,59). Few directly examine valence effects through gain-loss contrasts; therefore, more information on negative incentive processing is needed in addicted groups. Allostatic models suggest neuroadaptations related to negative reinforcement as central to the addiction cycle particularly during protracted abstinence(3). Finally, anticipatory-outcome phase contrasts could provide an axiomatic approach to the reward-prediction-error hypothesis(64).

Another source of variance largely unexplored on the MIDT is the role of counterfactual thinking in which responses to a given trial are related to previous trial performance. Cognitive biases, particularly in some addicted populations, could produce mixed emotions as an individual may have perceived hitting the target, or have a different response to neutral trials. Although experimental groups mostly do not differ in subjective ratings on different trials, these ratings are collected upon scan completion and do not necessarily reflect responses at each given trial. Nonetheless, how best to do so is complicated as collecting information on a person's expectation and response to each trial would interrupt the flow of the task and alter its essence(65).

With only a few exceptions, most study samples to date are relatively small (<20; Table 1); improvements in amalgamating data across scanners will aid in further substantiating findings. Efforts to combine MIDT data across sites should be promoted to increase sample sizes and promote addiction research. Nonetheless, extant findings highlight the importance of verifying the presence or absence of drugs or drug metabolites through urine screens and careful characterization of smoking status. In this way, the MIDT may help characterize neuroadaptations of anticipatory incentive signaling occurring in acute and extended periods of drug self-administration and abstinence. Divergent results across abstinent, recreational-using and addicted populations demonstrate complexities in interpreting findings. Moreover, characterizing how impulsivity and other addiction-related features relate to anticipatory striatal signaling over time will be important in understanding how anticipatory processes recover/adjust following protracted abstinence.

### **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgments

Support was provided by the following Grants: National Institutes of Health grants P20-DA027844, RL1-AA017539, P50-DA09241, R01-DA035058. Support was also provided by the following grants: a Center of Excellence in Gambling Research Grant and an Early Stage Investigator Grant from the National Center for Responsible Gaming. The contents of the manuscript are solely the responsibility of the authors and do not necessarily represent the official views of any of the funding agencies.

### References

- Knutson B, Greer SM. Anticipatory affect: neural correlates and consequences for choice. Philos Trans R Soc Lond B Biol Sci. 2008; 363:3771–3786. [PubMed: 18829428]
- Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs. 2000; 32(Suppl):i–iv. 1–112. [PubMed: 11280926]
- Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci. 2005; 8:1442–1444. [PubMed: 16251985]
- 4. Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl). 2007; 191:391–431. [PubMed: 17072591]
- 5. Redish AD. Addiction as a computational process gone awry. Science. 2004; 306:1944–1947. [PubMed: 15591205]
- O'Doherty J, Dayan P, Schultz J, Deichmann R, Friston K, Dolan RJ. Dissociable roles of ventral and dorsal striatum in instrumental conditioning. Science. 2004; 304:452–454. [PubMed: 15087550]
- Breiter HC, Aharon I, Kahneman D, Dale A, Shizgal P. Functional imaging of neural responses to expectancy and experience of monetary gains and losses. Neuron. 2001; 30:619–639. [PubMed: 11395019]
- Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2010; 35:4–26. [PubMed: 19812543]
- Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2001; 21:1034–1057.

- Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998; 80:1–27. [PubMed: 9658025]
- Knutson B, Adams CM, Fong GW, Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci. 2001; 21:RC159. [PubMed: 11459880]
- Knutson B, Fong GW, Adams CM, Varner JL, Hommer D. Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport. 2001; 12:3683–3687. [PubMed: 11726774]
- Knutson B, Westdorp A, Kaiser E, Hommer D. FMRI visualization of brain activity during a monetary incentive delay task. Neuroimage. 2000; 12:20–27. [PubMed: 10875899]
- Fiorillo CD, Tobler PN, Schultz W. Discrete coding of reward probability and uncertainty by dopamine neurons. Science. 2003; 299:1898–1902. [PubMed: 12649484]
- Barto AG, Sutton RS. Simulation of anticipatory responses in classical conditioning by a neuron-like adaptive element. Behav Brain Res. 1982; 4:221–235. [PubMed: 6277346]
- Abler B, Walter H, Erk S, Kammerer H, Spitzer M. Prediction error as a linear function of reward probability is coded in human nucleus accumbens. Neuroimage. 2006; 31:790–795. [PubMed: 16487726]
- Hollerman JR, Schultz W. Dopamine neurons report an error in the temporal prediction of reward during learning. Nat Neurosci. 1998; 1:304–309. [PubMed: 10195164]
- Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2010; 35:217–238. [PubMed: 19710631]
- 19. Knutson B, Katovich K, Suri G. Inferring affect from fMRI data. Trends in cognitive sciences. 2014
- Knutson B, Wimmer GE. Splitting the difference: how does the brain code reward episodes? Ann N Y Acad Sci. 2007; 1104:54–69. [PubMed: 17416922]
- Chase HW, Eickhoff SB, Laird AR, Hogarth L. The neural basis of drug stimulus processing and craving: an activation likelihood estimation meta-analysis. Biol Psychiatry. 70:785–793. [PubMed: 21757184]
- 22. Konova AB, Moeller SJ, Tomasi D, Parvaz MA, Alia-Klein N, Volkow ND, et al. Structural and behavioral correlates of abnormal encoding of money value in the sensorimotor striatum in cocaine addiction. The European journal of neuroscience. 2012; 36:2979–2988. [PubMed: 22775285]
- Knutson B, Fong GW, Bennett SM, Adams CM, Hommer D. A region of mesial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI. Neuroimage. 2003; 18:263–272. [PubMed: 12595181]
- Kelley AE. Ventral striatal control of appetitive motivation: role in ingestive behavior and rewardrelated learning. Neurosci Biobehav Rev. 2004; 27:765–776. [PubMed: 15019426]
- 25. Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci. 2004; 5:483–494. [PubMed: 15152198]
- Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction. 2000; 95(Suppl 2):S91–117. [PubMed: 11002906]
- Ikemoto S, Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Brain Res Rev. 1999; 31:6–41. [PubMed: 10611493]
- Atallah HE, Lopez-Paniagua D, Rudy JW, O'Reilly RC. Separate neural substrates for skill learning and performance in the ventral and dorsal striatum. Nat Neurosci. 2007; 10:126–131. [PubMed: 17187065]
- 29. Reading PJ, Dunnett SB, Robbins TW. Dissociable roles of the ventral, medial and lateral striatum on the acquisition and performance of a complex visual stimulus-response habit. Behav Brain Res. 1991; 45:147–161. [PubMed: 1789923]
- 30. Everitt BJ, Robbins TW. From the ventral to the dorsal striatum: devolving views of their roles in drug addiction. Neurosci Biobehav Rev. 2013; 37:1946–1954. [PubMed: 23438892]
- Bayer HM, Glimcher PW. Midbrain dopamine neurons encode a quantitative reward prediction error signal. Neuron. 2005; 47:129–141. [PubMed: 15996553]
- 32. Schott BH, Minuzzi L, Krebs RM, Elmenhorst D, Lang M, Winz OH, et al. Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. J Neurosci. 2008; 28:14311–14319. [PubMed: 19109512]

- 33. Urban NB, Slifstein M, Meda S, Xu X, Ayoub R, Medina O, et al. Imaging human reward processing with positron emission tomography and functional magnetic resonance imaging. Psychopharmacology (Berl). 2012; 221:67–77. [PubMed: 22052081]
- Zald DH, Boileau I, El-Dearedy W, Gunn R, McGlone F, Dichter GS, et al. Dopamine transmission in the human striatum during monetary reward tasks. J Neurosci. 2004; 24:4105–4112. [PubMed: 15115805]
- 35. Hakyemez HS, Dagher A, Smith SD, Zald DH. Striatal dopamine transmission in healthy humans during a passive monetary reward task. Neuroimage. 2008; 39:2058–2065. [PubMed: 18063390]
- 36. Asensio S, Romero MJ, Romero FJ, Wong C, Alia-Klein N, Tomasi D, et al. Striatal dopamine D2 receptor availability predicts the thalamic and medial prefrontal responses to reward in cocaine abusers three years later. Synapse. 64:397–402. [PubMed: 20034014]
- Phillips PE, Stuber GD, Heien ML, Wightman RM, Carelli RM. Subsecond dopamine release promotes cocaine seeking. Nature. 2003; 422:614–618. [PubMed: 12687000]
- Stuber GD, Roitman MF, Phillips PE, Carelli RM, Wightman RM. Rapid dopamine signaling in the nucleus accumbens during contingent and noncontingent cocaine administration. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2005; 30:853–863. [PubMed: 15549053]
- Grace AA. The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction. 2000; 95(Suppl 2):S119–128. [PubMed: 11002907]
- 40. Hommer DW, Bjork JM, Gilman JM. Imaging brain response to reward in addictive disorders. Ann N Y Acad Sci. 2011; 1216:50–61. [PubMed: 21272010]
- Croxson PL, Walton ME, O'Reilly JX, Behrens TE, Rushworth MF. Effort-based cost-benefit valuation and the human brain. J Neurosci. 2009; 29:4531–4541. [PubMed: 19357278]
- Wrase J, Schlagenhauf F, Kienast T, Wustenberg T, Bermpohl F, Kahnt T, et al. Dysfunction of reward processing correlates with alcohol craving in detoxified alcoholics. Neuroimage. 2007; 35:787–794. [PubMed: 17291784]
- Beck A, Schlagenhauf F, Wustenberg T, Hein J, Kienast T, Kahnt T, et al. Ventral striatal activation during reward anticipation correlates with impulsivity in alcoholics. Biol Psychiatry. 2009; 66:734– 742. [PubMed: 19560123]
- 44. Peters J, Bromberg U, Schneider S, Brassen S, Menz M, Banaschewski T, et al. Lower ventral striatal activation during reward anticipation in adolescent smokers. Am J Psychiatry. 2011; 168:540–549. [PubMed: 21362742]
- Bjork JM, Smith AR, Chen G, Hommer DW. Mesolimbic recruitment by nondrug rewards in detoxified alcoholics: effort anticipation, reward anticipation, and reward delivery. Human brain mapping. 2012; 33:2174–2188. [PubMed: 22281932]
- 46. Bjork JM, Smith AR, Hommer DW. Striatal sensitivity to reward deliveries and omissions in substance dependent patients. Neuroimage. 2008; 42:1609–1621. [PubMed: 18672069]
- Rose EJ, Ross TJ, Salmeron BJ, Lee M, Shakleya DM, Huestis MA, et al. Acute nicotine differentially impacts anticipatory valence- and magnitude-related striatal activity. Biol Psychiatry. 2013; 73:280– 288. [PubMed: 22939991]
- van Hell HH, Vink M, Ossewaarde L, Jager G, Kahn RS, Ramsey NF. Chronic effects of cannabis use on the human reward system: an fMRI study. Eur Neuropsychopharmacol. 2010; 20:153–163. [PubMed: 20061126]
- 49. Nestor L, Hester R, Garavan H. Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. Neuroimage. 2010; 49:1133–1143. [PubMed: 19631753]
- 50. Jia Z, Worhunsky PD, Carroll KM, Rounsaville BJ, Stevens MC, Pearlson GD, et al. An initial study of neural responses to monetary incentives as related to treatment outcome in cocaine dependence. Biol Psychiatry. 2011; 70:553–560. [PubMed: 21704307]
- 51. Bustamante JC, Barros-Loscertales A, Costumero V, Fuentes-Claramonte P, Rosell-Negre P, Ventura-Campos N, et al. Abstinence duration modulates striatal functioning during monetary reward processing in cocaine patients. Addict Biol. 2013

- 52. Patel KT, Stevens MC, Meda SA, Muska C, Thomas AD, Potenza MN, et al. Robust changes in reward circuitry during reward loss in current and former cocaine users during performance of a monetary incentive delay task. Biol Psychiatry. 2013; 74:529-537. [PubMed: 23778289]
- 53. Andrews MM, Meda SA, Thomas AD, Potenza MN, Krystal JH, Worhunsky P, et al. Individuals family history positive for alcoholism show functional magnetic resonance imaging differences in reward sensitivity that are related to impulsivity factors. Biol Psychiatry. 2011; 69:675–683. [PubMed: 21126735]
- 54. Association, AP. Diagnostic and statistical manual of mental disorders. 5th. Arlington, VA: American Psychiatric Publishing; 2013.
- 55. Balodis IM, Kober H, Worhunsky PD, Stevens MC, Pearlson GD, Potenza MN. Diminished frontostriatal activity during processing of monetary rewards and losses in pathological gambling. Biol Psychiatry. 2012; 71:749-757. [PubMed: 22336565]
- 56. Choi JS, Shin YC, Jung WH, Jang JH, Kang DH, Choi CH, et al. Altered brain activity during reward anticipation in pathological gambling and obsessive-compulsive disorder. PLoS One. 2012; 7:e45938. [PubMed: 23029329]
- 57. Yau WY, Zubieta JK, Weiland BJ, Samudra PG, Zucker RA, Heitzeg MM. Nucleus accumbens response to incentive stimuli anticipation in children of alcoholics: relationships with precursive behavioral risk and lifetime alcohol use. J Neurosci. 2012; 32:2544–2551. [PubMed: 22396427]
- 58. Knutson B, Bjork JM, Fong GW, Hommer D, Mattay VS, Weinberger DR. Amphetamine modulates human incentive processing. Neuron. 2004; 43:261-269. [PubMed: 15260961]
- 59. Schouw ML, De Ruiter MB, Kaag AM, van den Brink W, Lindauer RJ, Reneman L. Dopaminergic dysfunction in abstinent dexampletamine users: results from a pharmacological fMRI study using a reward anticipation task and a methylphenidate challenge. Drug Alcohol Depend. 2012; 130:52-60. [PubMed: 23142493]
- 60. Jansma JM, van Hell HH, Vanderschuren LJ, Bossong MG, Jager G, Kahn RS, et al. THC reduces the anticipatory nucleus accumbens response to reward in subjects with a nicotine addiction. Transl Psychiatry. 2013; 3:e234. [PubMed: 23443360]
- 61. van Hell HH, Jager G, Bossong MG, Brouwer A, Jansma JM, Zuurman L, et al. Involvement of the endocannabinoid system in reward processing in the human brain. Psychopharmacology (Berl). 2012; 219:981-990. [PubMed: 21822593]
- 62. Schneider S, Peters J, Bromberg U, Brassen S, Miedl SF, Banaschewski T, et al. Risk taking and the adolescent reward system: a potential common link to substance abuse. Am J Psychiatry. 2012; 169:39-46. [PubMed: 21955931]
- 63. Filbey FM, Dunlop J, Myers US. Neural effects of positive and negative incentives during marijuana withdrawal. PLoS One. 2013; 8:e61470. [PubMed: 23690923]
- 64. Rutledge RB, Dean M, Caplin A, Glimcher PW. Testing the reward prediction error hypothesis with an axiomatic model. J Neurosci. 2010; 30:13525-13536. [PubMed: 20926678]
- 65. Henderson SE, Norris CJ. Counterfactual thinking and reward processing: an fMRI study of responses to gamble outcomes. Neuroimage. 2013; 64:582-589. [PubMed: 22974555]

NIH-PA Author Manuscript

| :                      | ;                             |            | 7.11<br>1  |         | ,         |     | -                          | ••••          | ;             | :  |   |
|------------------------|-------------------------------|------------|------------|---------|-----------|-----|----------------------------|---------------|---------------|--|---|
| r oputation            | Auulor<br>(year)              | Group M/F  | M/F        | Screen? | Analysis  |     | Contrast 1                 | Surfactar     | Coortinates   | corretations<br>with Striatal<br>Response  | COMMENTS  |
|                        | Wrase et<br>al., 2007<br>(42) | 16M        | 16M        | 5       | WB<br>ROI | × \ | Gain > Neutral             | $\rightarrow$ | -16,12,-4     | - Alcohol<br>Craving in AD<br>negatively<br>correlates with<br>bilateral VS<br>activation<br>(-8,15,4<br>& 15,4  | <ul> <li>AD in-patient detoxification treatment</li> <li>controlled for smoking status</li> </ul>                                       |
|                        |                               |            |            |         |           | •   | Loss > Neutral             | $\rightarrow$ | -16,12,-4     |  |   |
| Alcohol Dependence(AD) | Bjork et al.,<br>2008 (46)    | 12M<br>11F | 12M<br>11F |         | ROI       | ×   | Gain > Neutral             |               | TC: ±10,10,-4 | <ul> <li>HC group VS<br/>response<br/>correlated<br/>positively with<br/>self-reported<br/>excitement</li> <li>collapsed<br/>across groups,<br/>VS signal<br/>positively<br/>correlates with<br/>self-reported<br/>impulsivity<br/>scores</li> </ul> | <ul> <li>AD inpatients; high CD comorbidity + other substances</li> <li>all smokers</li> <li>inclusion of frustration trials</li> </ul> |
|                        |                               |            |            |         |           |     | Loss > Neutral             |               |               |  |   |
|                        | Beck et al.,<br>2009 (43)     | M61        | M61        |         | WB<br>ROI | × \ | Gain > Neutral             | $\rightarrow$ | 12,15,-6      | - VS activity<br>negatively<br>correlates with<br>self-reported<br>impulsivity on<br>the Barratt<br>Impulsivity<br>Scale.<br>including<br>Cognitive,<br>Nonplanning<br>and Motor<br>subscales  | - controlled for smoking status   |
|                        |                               |            |            |         |           |     | Loss > Neutral             | ↓ (trend)     |               |  |   |
|                        | Bjork et al.,<br>2012 (45)    | 15M<br>14F | 12M<br>11F | ⊃       | WB<br>ROI | >   | Pre-response: Gain Neutral |               | TC: ±8,11,0   |  | AD inpatients; high CD     comorbidity + other substances   |

NIH-PA Author Manuscript

Table 1

| ments                                     | <ul> <li>all smokers</li> <li>Two-stage anticipatory cuing:</li> <li>Pre-response reward<br/>anticipation</li> <li>Post-response reward<br/>anticipation</li> <li>Loss trials not included in MIDT<br/>task</li> </ul> | <ul> <li>AD group contrast of WIN&gt;HIT trials in the VS did not survive multiple-comparison correction</li> </ul>  | - modified paradigm with 2 | <ul> <li>antreparoty pnases (same as rated et al., 2013; Balodis et al., 2012):</li> <li>A1= prospectof gain + motorpreparation</li> <li>A2 = anticipation</li> <li>Loss trial results not reported</li> </ul> | - decreased VS activity was driven<br>by the COAs with low-risk<br>drinking   |
|---|--|--|----------------------------|--|---|
| Com                                       |  |  |                            | <b>I</b>   |   |
| Correlations<br>with Striatal<br>Response |  | - Across groups,<br>uncorrected VS<br>activity during<br>post-response<br>reward<br>anticipation on<br>low rewards<br>positively<br>correlates with<br>self-reported<br>impulsivity on<br>the NEO-IF |                            | VS activity negatively<br>correlates with self-reported<br>compulsivity and reward/<br>punish ment sensitivity   | <ul> <li>Across the entire sample: positive correlation with drinks per week (trend at loss level)</li> <li>Within COAs: positive correlation with drinks per week, lifetime alcohol volume, externalizing</li> </ul> |
| Coordinates                               |  |  | Caudate: -21,-36,18        | VS: 9,12,-6  | -10, 13, -8 & 11, 13, -8  |
| Striatal<br>Response                      |  | 1  | $\leftarrow$               | $\rightarrow$  | $\rightarrow$   |
| Phase/<br>Contrast                        |  | Post-response: Win > Hit   | A1 Gain > baseline         | A2 Gain > baseline   | Gain > Neutral  |
| MC  |  |  | ``                         | >  | <b>``</b>   |
| Image<br>Analysis                         |  |  | WB                         | 102  | WB<br>ROI   |
| Urine<br>Screen?                          |  |  |                            |  | ×   |
| HC<br>M/F                                 |  |  | TM<br>TO                   | 171  | 12M<br>8F   |
| Clinical<br>Group M/F                     |  |  | 10M                        | -07  | 12M<br>8F   |
| Author<br>(year)                          |  |  | Andrews et                 | a 2011<br>(53)   | Yau et al.,<br>2012 (57)  |
| Population                                |  |  |                            |  | Children of Alcoholics  |

NIH-PA Author Manuscript

|   |  |   | -                               |   |  |  |                    |                    |                    |   |                |   | _              |
|---|--|---|---------------------------------|---|--|--|--------------------|--------------------|--------------------|---|----------------|---|----------------|
| Comments                                  |  | <ul> <li>Treatment-seeking, cocaine use ~5<br/>days</li> <li>Loss trial results not reported</li> </ul> | - neutral condition requires no | response<br>Loss trial results not reported                               | <ul> <li>modified paradigm with 2<br/>anticipatory phases (same as<br/>Andrews et al., 2010; Balodis et al.,<br/>2012):</li> </ul> | <ul> <li>A1 = prospectof gain +<br/>motorpreparation</li> <li>A2 = anticipation</li> </ul> |                    |                    |                    | <ul> <li>0.25mg/kg oral<br/>dextroamphetamine (AMPH)</li> <li>Relative to placebo, AMPH<br/>reduced activity to higher<br/>magnitude wins, but increased<br/>striatal activity to losses</li> </ul> |                | <ul> <li>used voxels that showed a<br/>significant interaction effect to<br/>create a mask to determine mean<br/>percent BOLD change</li> </ul> |                |
| Correlations<br>with Striatal<br>Response | risk during both<br>win and loss<br>anticipation | 1   |                                 | - Left caudate<br>correlates<br>positively with<br>months of<br>treatment | <ul> <li>in former CD<br/>group, VS<br/>activity<br/>negatively</li> </ul>   | correlated with<br>abstinence<br>(uncorrected)   |                    |                    |                    | - Striatal activity<br>during both<br>placebo and<br>AMPH<br>conditions<br>correlated<br>positively with<br>self-rated<br>positive arousal  |                | 1   |                |
| Coordinates                               |  | Caudate 10,8,3  | 10,8,0 & -10,10,-2              | Caudate 12,5,19   | Custom-drawn   |  |                    |                    |                    | TC: ±11,12,-2-  |                |   |                |
| Striatal<br>Response                      |  | ~   |                                 | $\rightarrow$   |  |  |                    |                    |                    | $\rightarrow$   | ~              | $\rightarrow$   |                |
| Phase/<br>Contrast                        |  | Gain > Neutral  | Gain > Neutral                  | Gain > Neutral  | A1 Gain > baseline   |  | A2 Gain > baseline | A1 Loss > baseline | A2 Loss > baseline | Gain > Neutral  | Loss > Neutral | Gain > Neutral  | Loss > Neutral |
| MC  |  | >   | >                               |   | `  |  |                    | [                  | I                  | ×   |                | ×   |                |
| Image<br>Analysis                         |  | ROI   | ROI                             |   | ROI  |  |                    |                    |                    | ROI   |                | ROI   |                |
| Urine<br>Screen?                          |  | ×   | ⊃                               |   | 5  |  |                    |                    |                    | ×   |                | 5   |                |
| HC<br>M/F                                 |  | 12M<br>8F   | 18M                             |   | 26M<br>21F   |  |                    |                    |                    | 6M<br>2F  |                | 8M  |                |
| Clinical<br>Group M/F                     |  | 12M<br>8F   | 17M                             |   | Current: 24M<br>18F Former: 26M 9F   |  |                    |                    |                    | 1   |                | Recreational users: 8M  |                |
| Author<br>(year)                          |  | Jia,<br>Worhun-<br>sky et al.,<br>2011 (50)   | Bustame-                        | nte et al.,<br>2013 (51)  | Patel et al.,<br>2013 (52)   |  |                    |                    |                    | Knutson et<br>al., 2004<br>(58)   |                | Schouw et<br>al., 2012<br>(59)  |                |
| Population                                |  |   | <b></b>                         | -   | Cocaine Dependence (CD)  |  |                    |                    |                    | Stimulant Challence Studies   |                |   |                |

Biol Psychiatry. Author manuscript; available in PMC 2016 March 01.

**NIH-PA** Author Manuscript

NIH-PA Author Manuscript

| Population              | Author<br>(year)               | Clinical<br>Group M/F  | HC<br>M/F  | Urine<br>Screen? | Image<br>Analysis | MC | Phase/<br>Contrast      | Striatal<br>Response | Coordinates                                  | Correlations<br>with Striatal<br>Response                                   | Comments   |
|-------------------------|--------------------------------|------------------------|------------|------------------|-------------------|----|-------------------------|----------------------|--|---|--|
|                         |                                |                        | 8M         |                  | ROI               | ×  | Gain > Neutral          | $\rightarrow$        |  |   | - 35mg oral methylphenidate  |
|                         |                                | Recreational users: 8M |            | ⊃                | ROI               | ×  | Gain > Neutral          |                      |  |   |  |
|                         | Rose et al.,<br>2013 (47)      | 13M<br>15F             | 16M<br>12F | ⊃                | WB<br>ROI         | >> | PRIME-1 Valence         | $\rightarrow$        | Caudate -13,10, 0<br>9,12,2 (TC)             |   | Modified MIDT with 2 primes; PRIME-1<br>representing valence (Gain>Loss) PRIME-2<br>representing magnitude |
|                         |                                | 13M<br>15T             | 16M        |                  | WB                | >` | PRIME-1 Valence         | $\rightarrow$        | VS -13,10,-8 (TC)                            |   | - Smokers with nicotine patch  |
|                         |                                | HCT                    | 12F        |                  | KOI               | \$ | PRIME-2 Gain Magn itude | ~                    | Caudate -7,6,6 (TC)                          |   | relative to non- smoking HC group<br>(without patch)   |
|                         |                                |                        |            |                  |                   | •  | PRIME-2 Loss Magn itude | ~                    | Caudate -10,1,1 4<br>(TC)                    |   |  |
| Nicotine Dependence(ND) |                                | 13M<br>15F             | 1          |                  |                   |    | PRIME-1 Valence         | →                    | Putamen 24, 4,4 (TC)                         | - VS activity<br>negatively<br>associated with<br>plasma nicotine<br>levels |  |
|                         | Jansmaet<br>al., 2013          | 10M                    | 11M        | ⊃                | ROI               | ×  | Gain > Neutr al         | $\rightarrow$        | ±12,14,-8                                    |   | <ul> <li>administration of 6mg THC or<br/>placebo</li> </ul>   |
|                         | (09)                           |                        |            |                  |                   |    |                         |                      |  |   | ► Loss trial results not reported  |
|                         | Van Hell et                    | 13M1F Smokers: 11M3F   | 11M2F      |                  | WB<br>POI         | `  | Gain > Neutral          | $\rightarrow$        | ±14,14,-8(TC)                                | 1   | <ul> <li>non-treatment seeking</li> </ul>  |
|                         | (48)                           |                        |            |                  |                   |    |                         |                      |  |   | ► Loss trial results not included in MIDT task   |
|                         |                                |                        |            |                  |                   |    |                         |                      |  |   | <ul> <li>negative urine screens for THC in<br/>almost all participants</li> </ul>                          |
|                         |                                |                        |            |                  |                   |    |                         |                      |  |   | <ul> <li>decreased VS in both Smokers and<br/>cannabis users relative to HCs</li> </ul>                    |
| Marijuana Dependence    | Nestor et<br>al., 2010         | 14M                    | 14M        | ∪ +THC           | WB                | >  | Gain > Baseline         | ~                    | 20,8,-4                                      | VS activity during 'win'<br>correlates positively with # of                 | MIDT version collapsed across     magnitude  |
|                         | (49)                           |                        |            |                  |                   |    |                         |                      |  | reported lifetime joints<br>smoked  | <ul> <li>all MD participants had positive<br/>THC urine toxicology</li> </ul>                              |
|                         |                                |                        |            |                  |                   |    | Loss > Baseline         |                      |  |   |  |
|                         | Filbey et<br>al., 2013<br>(63) | 47M<br>12F             | 5M<br>22F  | ∪ +THC           | WB                | >  | Gain > Neutral          |                      | MNI extents on x:<br>8-16; y=15-6;<br>z=-412 |   | <ul> <li>required positive urinalysis for<br/>THC metabolites, but excluded for<br/>other drugs</li> </ul> |
|                         |                                |                        |            |                  |                   |    |                         |                      |  |   | <ul> <li>HC group showed no sig.<br/>difference during either incentive</li> </ul>                         |

Т

т

т

Page 17

т

Biol Psychiatry. Author manuscript; available in PMC 2016 March 01.

NIH-PA Author Manuscript

ſ

NIH-PA Author Manuscript

| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$  | ·                | Author<br>(year)                | Clinical<br>Group M/F | HC<br>M/F | Urine<br>Screen? | Image<br>Analysis | MC | Phase/<br>Contrast | Striatal<br>Response | Coordinates                       | Correlations<br>with Striatal<br>Response   | Comments  |
|--|------------------|---------------------------------|-----------------------|-----------|------------------|-------------------|----|--------------------|----------------------|-----------------------------------|---|---|
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$  |                  |                                 |                       |           |                  |                   |    |                    |                      |                                   |   | condition (gain or loss)–may be<br>driving effect?  |
|  |                  |                                 |                       |           |                  |                   |    | Loss > Baseline    |                      |                                   |   |   |
| Balodiset 10M 10M $4F$ $4F$ $10$ W $4F$ $10$ W $4F$ $10$ W $10$ $10$ $10$ $10$ $10$ $10$ $10$ $10$   | a<br>a           | an Hell et<br>al., 2012<br>(61) |                       | 11M       | 5                | ROI               | ×  | Gain > Neutral     | 1                    | Dorsal caudate -8,4,4<br>& 12,8,0 |   | <ul> <li>6mg THC administration or placebo</li> <li>ROI based on pooled group activation maps:</li> <li>Loss trial results not included in MIDT task</li> </ul> |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $  | <sup>_ م</sup> ا | alodiset                        | 10M                   | 10M       | □                | WB                | `` | A1 Gain            | $\rightarrow$        |                                   |   | - modified paradigm with 2  |
| Choice al., $15M$ $ISM$  |                  | al., 2012<br>(55)               | Ч                     | 4         |                  | KU                | \$ | A2 Gain            | $\rightarrow$        | 10,12,-11                         | VS activity correlates<br>negatively with self-reported<br>motor impulsivity  | anticipatory phases (same as<br>Andrews et al., 2010; Patel et al.,<br>2013):<br>• • • • • • • • • • • • • • • • • • •  |
| Choict al.,<br>2012 (56)       Loss       ↓       -10,12,-11       VS activity correlates<br>negatively with self-reported<br>impulsivity and cognitive<br>impulsivity on the Barratt       •       A2 = anticipation         Choict al.,<br>2012 (56)       15M       15M       X       WB       Gain > Neutral       ↓       0,3,0       •       •       A2 = anticipation         Choict al.,<br>2012 (56)       15M       15M       X       WB       Gain > Neutral       ↓       0,3,0       •       •       0.0 concretidities in the GD group         Choict al.,<br>2012 (56)       15M       15M       X       WB       Gain > Neutral       ↓       0,3,0       •       •       0.0 concretidities in the GD group         Choict al.,<br>2012 (56)       15M       15M       10       0,3,0       •       •       0.0 concretidities in the GD group         Choict al.,<br>2012 (56)       1       0       0,3,0       •   |                  |                                 |                       |           |                  |                   |    | A1 Loss            | $\uparrow$           |                                   |   | motor prospector gain +   |
| Choi et al.,<br>2012 (56)     L5M     15M     15M     MB     Gain > Neutral     U     0,3,0     -     no comorbidities in the GD group<br>(except smoking) - duration of<br>illness < 5 years       2012 (56)     Image: Solution of the state of the sta |                  |                                 |                       |           |                  |                   |    | A2 Loss            | $\rightarrow$        | -10,12,-11                        | VS activity correlates<br>negatively with self-reported<br>impulsivity and cognitive<br>impulsivity on the Barratt<br>Impulsivity Scale | A2 =anticipation  |
| Loss > Neutral $\downarrow$ 0,3,0  | 7 CI             | hoi et al.,<br>012 (56)         | ISM                   | 15M       | ×                | WB<br>ROI         |    | Gain > Neutral     | $\rightarrow$        | 0,3,0                             |   | <ul> <li>no comorbidities in the GD group<br/>(except smoking) – duration of<br/>illness &lt; 5 years</li> </ul>  |
|  |                  |                                 |                       | 1         |                  |                   |    | Loss > Neutral     | $\rightarrow$        | 0,3,0                             |   |   |

# Control: THC =Tetrahydrocannabinol; TC= Talairach Coordinates; MNI=Montreal Neurological Institute Coordinates (x,y,z), unless stated, all coordinates are in MNI.

Г